Clinical trial

CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function

NCT01678794

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2012-02-01

PhasePHASE1 / PHASE2

Study timeline

Study start (unknown)2012-02-01Date precision: month

Registry last updated2021-11-18

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Cardiorenal Syndrome (CRS)unresolved

Interventions

CandesartanDRUG · verified · RxNorm: candesartan

PlaceboDRUG

Sponsors & collaborators

Mayo Cliniclead sponsor

National Heart, Lung, and Blood Institute (NHLBI)collaborator

Mapped research locations

RochesterMinnesota, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01678794 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.